Avacta Therapeutics Unveils Key Presentations for AACR Meeting
Avacta Therapeutics to Present at the AACR Annual Meeting
Avacta Therapeutics (LSE: AVCT), a leading life sciences company specializing in advanced peptide drug conjugates (PDC) that deliver powerful anti-tumor agents directly to cancer sites, is set to present groundbreaking research at the highly anticipated American Association for Cancer Research (AACR) Annual Meeting.
This annual event, renowned for bringing together the brightest minds in cancer research, will take place over several days, featuring a host of insightful sessions focused on cutting-edge methodologies and promising therapeutic strategies in oncology.
Highlights of Avacta's Presentations
Avacta's presence at the AACR will include three comprehensive poster presentations that showcase the latest data from the Company’s proprietary pre|CISION® platform. This innovative technology aims to revolutionize how we approach cancer treatment by selectively targeting and activating drugs within the tumor microenvironment.
Presentation Details and Topics
The first presentation will focus on AVA6000, a peptide drug conjugate that incorporates doxorubicin linked to a peptide moiety specifically designed for cleavage by fibroblast activation protein (FAP) in the tumor. This targeted approach not only enhances the drug's efficacy but also minimizes adverse effects on healthy tissues.
The second poster will delve into AVA6103, which features pre|CISION® linked to exatecan, a potent topoisomerase I inhibitor. This presentation will elevate discussions around how this innovative PDC can optimize therapeutic outcomes for cancer patients.
The third presentation will provide a deep dive into the analytical understanding of fibroblast activation protein-alpha (FAP?), the critical protease fundamental to the pre|CISION® platform. By elucidating its role within the tumor microenvironment, Avacta aims to empower further advancements in targeted cancer therapies.
Further Information About the Presentations
Joining like-minded professionals at the AACR Annual Meeting, Avacta looks forward to engaging discussions that will underpin future advancements in cancer therapeutics.
Session Breakdown
The details of Avacta's poster presentations are outlined as follows:
Abstract Number: #3139: The novel PDC AVA6103 is a FAP-enabled pre|CISION® medicine targeting exatecan, a topoisomerase I inhibitor, for tumor microenvironment activation.
Session Title: Therapeutic Approach to Attack the Tumor Microenvironment
Date and Time: Monday, April 28, 2025, 2:00 - 5:00 p.m. CT
Abstract Number: #2699: Investigating fibroblast activation protein alpha (FAP?) as a therapeutic target for delivery of pre|CISION® cancer medicines.
Session Title: Targeting the Tumor Microenvironment: A Brave New World
Date and Time: Monday, April 28, 2025, 2:00 - 5:00 p.m. CT
Abstract Number: #CT15: Comparative pharmacokinetics and tumor activation of FAP-enabled pre|CISION® peptide drug conjugates.
Session Title: First-in-Human Phase I Clinical Trials 2
Date and Time: Tuesday, April 29, 2025, 9:00 a.m. - 12:00 p.m. CT
Contact Information for Avacta Therapeutics
For any inquiries regarding Avacta Therapeutics and its participation at the AACR Annual Meeting, please connect with the professionals below:
Avacta Group plc
Michael Vinegrad, Group Communications Director
Email: avacta@icrhealthcare.com
Investor Contact:
Renee Leck, THRUST Strategic Communications
Email: renee@thrustsc.com
Media Contact:
Carly Scaduto, Carly Scaduto Consulting
Email: Carly@carlyscadutoconsulting.com
Frequently Asked Questions
What is Avacta Therapeutics focusing on at the AACR meeting?
Avacta Therapeutics is presenting innovative research on its peptide drug conjugates and the pre|CISION® platform for targeted cancer therapy.
How does the pre|CISION® platform work?
The pre|CISION® platform utilizes FAP to deliver potent cancer therapies directly to tumors, minimizing damage to surrounding healthy tissue.
When will Avacta's presentations occur?
The presentations are scheduled for various times between April 28-29, 2025, during the AACR Annual Meeting.
What drug candidates is Avacta showcasing?
Avacta is highlighting AVA6000 and AVA6103, focusing on their unique mechanisms and therapeutic implications.
Who can I contact for more information about Avacta's AACR participation?
For detailed inquiries, you can contact any of the representatives listed above, including Michael Vinegrad or Renee Leck.
About The Author
Contact Olivia Taylor privately here. Or send an email with ATTN: Olivia Taylor as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.